Adverum Biotechnologies, Inc.

75 articles with Adverum Biotechnologies, Inc.

• Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference

  11/23/2020

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the Piper Sandler 32 nd Annual Virtual Healthcare Conference. Adverum’s video webcast will be accessible on demand beginning today at 10:00 am ET under Events and Presentations in the Investors section of the company's website. This webcast will

• Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

  11/14/2020

  Company to host webcast with Key Opinion Leaders to discuss new OPTIC data today, Saturday, November 14, 2020 at 7:30 am PT / 10:30 am ET

• Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2020 Financial Results

  11/5/2020

  Company to host conference call and webcast with KOLs to discuss new data from Cohorts 1-4 of OPTIC Phase 1 trial of ADVM-022 for wet AMD on November 14, 2020 at 7:30 am PT

• Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 Virtual

  10/20/2020

  -- Dr. Carl Regillo to present OPTIC data a t the R etina S ubspecialty D ay on  Friday, November 13, 2020 at 2:15 pm PT -- -- Company to host webcast with key opinion leaders on Saturday , November 14 , 2020 at 7 :30 a m PT --

• 

  BioSpace Movers & Shakers, Sept. 18

  9/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Adverum Biotechnologies Announces Appointment of Christopher J. Morrison, Ph.D. as Vice President, Process Science

  9/15/2020

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Christopher J. Morrison, Ph.D. joined the company as vice president, process development, reporting into Adverum’s chief technology officer Angela Thedinga. “Chris brings a wealth of AAV gene therapy experience and will lead the scale-up of our commercial manufacturing p

• Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock - Aug 13, 2020

  8/13/2020

  Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, announced the pricing of its underwritten public offering of 14,500,000 shares of its common stock at a public offering price of $13.00 per share.

• Adverum Biotechnologies Announces $200 Million Public Offering of Common Stock

  8/11/2020

  Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has commenced an underwritten public offering of $200 million of its common stock.

• Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update

  7/29/2020

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it will host a conference call and webcast on Monday, August 10, 2020 at 1:30 pm PT/4:30 pm ET to report its second quarter 2020 financial results and provide a corporate update.  

• 

  BioSpace Movers & Shakers, July 24

  7/24/2020

  Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.

• Adverum Biotechnologies Announces Appointment of Thomas Kochy as Vice President, Commercial and Program Strategy

  7/21/2020

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Thomas Kochy joined the company as vice president, commercial and program strategy. In this newly created position, Mr. Kochy will be responsible for leading commercial planning, product strategy, and program management. This position will report into Adverum’s president, L

• Adverum Biotechnologies Announces First Patient Randomized in Phase 2 INFINITY Trial of ADVM-022 Single Injection Gene Therapy for Diabetic Macular Edema (DME)

  7/13/2020

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was randomized in the INFINITY clinical trial to evaluate ADVM-022 for the treatment of diabetic macular edema (DME).

• Adverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC Phase 1 Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD

  7/6/2020

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the completion of patient dosing in Cohort 4 of OPTIC, a Phase 1 clinical trial, assessing a single intravitreal (IVT) injection of ADVM-022 in patients with wet age-related macular degeneration (AMD).

• 

  BioSpace Movers & Shakers, June 26

  6/26/2020

  Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.

• Adverum Biotechnologies Announces Appointment of Heikki Jouttijärvi as Vice President of Manufacturing

  6/25/2020

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Heikki Jouttijärvi joined the company as vice president, manufacturing

• 

  BioSpace Movers & Shakers, June 19

  6/19/2020

  Biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.

• Adverum Biotechnologies Announces Leadership Transition

  6/15/2020

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Laurent Fischer, M.D. has joined the company as its chief executive officer and a member of the board of directors.

• Adverum Biotechnologies to Participate in Goldman Sachs 41st Annual Global Healthcare Conference

  6/4/2020

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Thursday, June 11, 2020 at 3:50 pm EDT.

• Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results

  5/28/2020

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the initiation of INFINITY, a Phase 2,  multi-center, randomized, double-masked, active comparator-controlled trial to assess a single intravitreal (IVT) injection of ADVM-022 in patients with diabetic macular edema (DME).

• Adverum Biotechnologies Reports Positive Interim Data from Cohorts 1-3 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

  5/4/2020

  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new interim clinical data from Cohorts 1-3 of the OPTIC Phase 1 dose-ranging clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD) and provided a business update.